-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly unveiled the first batch of clinical data from its investigational next-generation FR-targeted ADC in platinum-sensitive ovarian cancer at the 2026 ESMO conference.

Zhitongcaijing·10/24/2026 06:33:00
Listen to the news
Eli Lilly unveiled the first batch of clinical data from its investigational next-generation FR-targeted ADC in platinum-sensitive ovarian cancer at the 2026 ESMO conference.